Please assess the completion status of the following clinical trial:

Trial Title: Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age greater than or equal to 18 years~2. Able to give informed consent~3. New diagnosis of AML, other than APL or poor-risk AML, as defined in section 3.2~Exclusion criteria:~1. Has already had a bone marrow biopsy and aspirate to assess remission status after induction therapy~2. Any debilitating medical or psychiatric illness that would preclude ability to give informed consent or receive optimal treatment and follow-up~3. Pregnancy: Women of childbearing potential who are β- HCG+

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- No Leukemia Stem Cells - Consolidation (Type: EXPERIMENTAL): Without LSC, standard cytarabine consolidation
- Leukemia Stem Cells - Consolidation (Type: EXPERIMENTAL): LSC present, randomized to cytarabine consolidation
- Leukemia Stem Cells - Transplant (Type: EXPERIMENTAL): LSC present, randomized to allogeneic transplant

Based on this trial design, predict the completion outcome and termination type (if applicable).